Le Lézard
Classified in: Health, Science and technology

Pursuing Parkinson's Disease Gene Therapies: Strategies & Operational Requirements, Upcoming Webinar Hosted by Xtalks


TORONTO, April 5, 2021 /PRNewswire-PRWeb/ -- While treatment of Parkinson's disease (PD) has traditionally been limited to dopamine replacement therapy to alleviate symptoms, gene therapy studies have recently evaluated both non-disease-modifying and disease-modifying transgenes for PD treatment, with encouraging results.

Non-disease-modifying therapies have improved symptomatology and disease-modifying strategies, including stopping PD-mediated cell death and/or regenerating lost neurons, and show potential in slowing disease progression. However, these studies face unique challenges due to their patient population and the complex regulatory considerations for these advanced therapies.

Conducting these trials requires careful attention to investigator and site selection and adherence to local regulatory and protocol design requirements. The need for long-term patient follow-up, potentially as long as 15 years, puts added demands on patients and sites.

Join expert speakers from Premier Research, Andreas Schreiner, M.D., Vice President, Medical Affairs Neuroscience and Analgesia; and Hanna Wide, M.S., Executive Director, Cell and Gene Therapy, in a live webinar on Wednesday, April 14, 2021 at 11am EDT (4pm BST/UK).

For more information, or to register for this event, visit Pursuing Parkinson's Disease Gene Therapies: Strategies & Operational Requirements.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Contact:
Sydney Perelmutter
Tel: +1 (416) 977-6555 x 352
Email: [email protected]

Media Contact

Sydney Perelmutter, Xtalks, (416) 977-6555 x352, [email protected]

 

SOURCE Xtalks


These press releases may also interest you

at 16:05
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today...

at 16:05
Biodesix, Inc. , a leading diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for the first quarter ended March 31, 2024, and provided a corporate update. "I am very pleased to announce...

at 16:05
Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today reported financial results for the first quarter ended March 31, 2024,...

at 16:05
Consensus Cloud Solutions, Inc. today reported financial results for the first quarter of 2024. "I am pleased with our Q1 performance. SoHo and Corporate revenues were ahead of expectations, which combined with our cost saving measures, produced a...

at 16:05
Porch Group, Inc. ("Porch Group" or "the Company") , a homeowners insurance and vertical software platform, today reported first quarter results through March 31, 2024, with total revenue of $115.4 million, which increased 32% compared to the prior...

at 16:05
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for the quarter ended March 31, 2024,...



News published on and distributed by: